Tilray Brands (TLRY) Change in Accured Expenses (2017 - 2026)
Tilray Brands' (TLRY) quarterly Change in Accured Expenses came in at $40.3 million in Q2 2026, up 168.6% YoY from $15.0 million in Q2 2025, and up 479.22% on a QoQ basis from -$10.6 million in Q1 2026.
Tilray Brands (TLRY) Change in Accured Expenses (2017 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 10 years of Change in Accured Expenses data on file, last reported at $40.3 million in Q2 2026.
- Quarterly Change in Accured Expenses rose 168.6% year-over-year to $40.3 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $19.4 million (up 184.58% YoY) and the FY2026 annual result came in at $19.4 million, up 184.58% from the prior year.
- Change in Accured Expenses climbed to $40.3 million in Q2 2026, from -$10.6 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $40.3 million in Q2 2026 to a low of -$18.0 million in Q4 2023.
- A 5-year average of $921111.1 and a median of -$5.7 million in 2022 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses plunged 1352.3% — and 2026, when it soared 168.6%.
- Tracing TLRY's Change in Accured Expenses over 5 years: stood at $4.3 million in 2022, then slumped by 515.73% to -$18.0 million in 2023, then gained by 9.01% to -$16.4 million in 2024, then surged by 68.32% to -$5.2 million in 2025, then soared by 878.79% to $40.3 million in 2026.
- The last three Change in Accured Expenses figures came in at $40.3 million (Q2 2026), -$10.6 million (Q1 2026), and -$5.2 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Tilray Brands | 516.11 Mn | 281.48 Mn | 90.52 Mn | 40.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 40.35 Mn |
| May 31, 2026 | 40.35 Mn |
| Feb 28, 2026 | -10.64 Mn |
| Feb 28, 2026 | -10.64 Mn |
| Nov 30, 2025 | -5.18 Mn |
| Nov 30, 2025 | -5.18 Mn |
| Aug 31, 2025 | -5.13 Mn |
| Aug 31, 2025 | -5.13 Mn |
| May 31, 2025 | 15.02 Mn |
| May 31, 2025 | 15.02 Mn |
| Feb 28, 2025 | -13.13 Mn |
| Feb 28, 2025 | -13.13 Mn |
| Nov 30, 2024 | -16.36 Mn |
| Nov 30, 2024 | -16.36 Mn |
| Aug 31, 2024 | -8.47 Mn |
| Aug 31, 2024 | -8.47 Mn |
| May 31, 2024 | 31.19 Mn |
| May 31, 2024 | 31.19 Mn |
| Feb 29, 2024 | -6.54 Mn |
| Feb 29, 2024 | -6.54 Mn |